Novel Oncology Therapies Require Innovative Methods in Oncology Modeling
May 16, 2023 |
Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.
Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.
Health technology assessment (HTA) agencies have long required evidence of long-term survival and lifetime estimates of quality of life before they will approve new treatments. Health economics and outcomes research analysts have relied on standard parametric models to extrapolate overall survival rates from clinical trial data to estimate quality of life.
This traditional approach identifies the statistical models that best fit the available data and then uses these models to predict outcomes over the lifetime. It worked well for traditional cancer treatments, including chemotherapy. However, many new oncology drugs have a different mechanism of action—including the possibility of delayed and prolonged response to treatment and, potentially, cure—which may not be accurately represented by these traditional models.
Applying standard models to novel oncology therapies may lead to inaccurate estimates of survival and/or quality-of-life benefits, which could cause HTA agencies to reject beneficial treatments. For patients to access potentially lifesaving medications, analysts need to use more sophisticated modeling methods that can accommodate the potentially complex hazard patterns associated with these treatments.
Choosing an oncology modeling method
Newer methods and techniques may better capture the potential value of innovative oncology treatments.
The appropriate modeling method can provide the foundation for an accurate assessment of the benefits associated with novel oncology therapies—a crucial step in gaining regulatory approval and getting treatment to those who need it. However, determining which model to use can be challenging.
In January 2020, the National Institute for Health and Care Excellence, Decision Support Unit issued Technical Support Document 21 (TSD 21), a guide to flexible methods for survival analysis. This document suggested some innovative modeling approaches, including cure models, mixture modeling, piecewise models and landmark approaches, and encouraged careful consideration of the tradeoff between short-term fit versus long-term assumptions. These newer methods aim to more accurately estimate the value of new drugs in terms of cost, life years and quality of life.
TSD 21, however, did not specify when—or under which circumstances—specific models should be used.
At present, guidance is limited as to when flexible models should be considered, and which might be most appropriate for a particular data set. An advisory board of seven international experts with in-depth knowledge of survival analysis and health technology assessment collaborated over the summer of 2021 to produce an algorithm that can be used to inform selection of flexible survival oncology models.
The algorithm, which consists of eight steps and four questions, was published in Value in Health journal in August 2022. It provides a systematic, evidence-based approach to justify the selection of extrapolation models for immunotherapeutic cancer medications, and, if followed, should reduce the risk of selecting inappropriate models that may underestimate the benefit of novel treatments.
Oncology modeling continues to play a vital role in determining (and demonstrating) the value of new cancer treatments, but traditional methods aren’t a good fit for new drugs that have prolonged responses. Flexible extrapolation models offer a better estimate of the value of new drugs. They offer cost-effective analyses of cancer immunotherapies and other innovative oncology therapies.
At OPEN Health, we use advanced survival modeling techniques as needed to demonstrate value. Our multidisciplinary teams have deep knowledge of oncology modeling and routinely help pharmaceutical companies navigate health technology assessments and joint clinical assessments.
Learn more about OPEN Health: https://www.openhealthgroup.com/
This content was provided by OPEN Health
Company Details
Latest Content from OPEN Health
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....
Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma
OPEN Health reflections on the World Orphan Drug Congress in Barcelona
Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
OPEN Health announces the integration of Pharmerit International into the group
OPEN Health has today announced the integration of Pharmerit International, a global leader in health economics and outcomes research (HEOR), into its group of companies.
OPEN Health mobilised to support outcomes with gene and other advanced therapies
Harnessing the power of collaborations to bring real insights and improve outcomes
Spotlight interview: 15 minutes on PR in pharma
Vicky Bramham, Managing Director, OPEN Health takes 15 minutes to answer some key questions on PR discipline.
OPEN Health PBC recognised as No. 1 independent creative agency
We’re No.1! PMLive have named OPEN Health Patient & Brand Communications as the no.1 independent creative healthcare agency. The aim of the PMLive Top 10 lists is to highlight those...